Trial Profile

A Prospective, Randomized, Single Center Pilot Study Comparing Patient and Graft Survival, Adverse Events and Tolerability of Zortress (Everolimus) Versus Rapamune (Sirolimus) in Combination With Low Dose Neoral(Cyclosporine) Dosed by C2 Monitoring, in Deceased and Living Donor Renal Transplant Recipients Under a Thymoglobulin (Antithymocyte Globulin) and Rapid Steroid Induction Protocol.

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 01 Dec 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Everolimus (Primary) ; Sirolimus (Primary) ; Antithymocyte globulin; Ciclosporin
Indications Renal transplant rejection
Focus Therapeutic Use

02 Nov 2021 Status changed from active, no longer recruiting to completed.
09 May 2017 Planned End Date changed from 1 Feb 2017 to 1 May 2018.
09 May 2017 Planned primary completion date changed from 1 Feb 2017 to 1 May 2018.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com